BioSpace News Archive

Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA at Independent Non-Executive Director.

Sanofi has delivered the first medicines from its Global Health Unit’s not-for-profit Impact brand portfolio to the Republic of Djibouti.

Theravance Biopharma, Inc. will report its third quarter 2023 financial results and provide a business update after market close on Tuesday, November 7, 2023.

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, Nov. 2, 2023, at 8:00 a.m. ET to report its third quarter 2023 financial results and other business highlights.

Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT).

Personalis, Inc . (Nasdaq: PSNL), a leader in precision oncology, today announced that a late-breaking abstract featuring data for the company’s NeXT Personal ® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection, has been accepted and selected for a proffered paper presentation at the 2023 European Society for Medical Oncology (ESMO) Congress, on October 21 in Madrid, Spain.

Kura Oncology, Inc. today announced that the first patient has been dosed in the FIT-001 Phase 1 dose-escalation trial of KO-2806, the Company’s next-generation farnesyl transferase inhibitor (FTI) for the treatment of advanced solid tumors.

Excision BioTherapeutics, Inc. today announced that interim clinical safety and biodistribution data will be presented at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, which will be held from October 24-27, 2023, in Brussels, Belgium.

Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss the Company’s third quarter 2023 financial results on Wednesday, November 1st , 2023 at 8:00 a.m. ET.

Akeso (9926. HK) announced the publication of the phase 1a/ 1b first-in-human study (COMPASSION-01) evaluating cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced solid tumors in Cell Reports Medicine, a sub-publication of Cell.